[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_103":104,"_105":59},"routes/en-gate",{"_102":59},"en-item-original",{"_11":12},"item",{"_13":14,"_15":16,"_17":18,"_19":18,"_20":-5,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":27,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":-5,"_40":42,"_43":-5,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":38,"_58":59,"_60":-5,"_61":62,"_63":64,"_65":38,"_66":59,"_67":68},"id","cgmgd0uacpvw0ldg90chnkblp","revision",2,"title","At the","originalTitle","summary","reason","source",{"_13":96,"_77":97,"_98":99,"_100":38,"_101":-5},"links",{"_93":94,"_68":95},"publishedAt","2026-04-20T12:02:59.000Z","discoveredAt","2026-10-22T11:08:55.027Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_86":87,"_88":49,"_89":-5,"_90":-5,"_91":92},"insight","digest","conferenceAbstracts","readingMode","full","author","Palleon_Pharma","language","body",{"_81":-5,"_68":82,"_83":84,"_85":59},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_75":76,"_77":78,"_79":-5,"_80":-5},"engagement",{"_69":70,"_71":70,"_72":73,"_74":73},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",4,"likes","replies",0,"reposts","slug","aacr-2026","name","AACR 2026 年会","topic","reading","zh","

At the
@AACR
Annual Meeting, we presented preclinical data on E-688/HLX316, a first-in-class B7-H3 targeted sialidase currently in a Phase 1 clinical trial with our partner
@HenliusBiotech
.

Read more in our latest press release:
https://
bit.ly/3QvC62f

#AACR26 #glycotime

","zhKind","translation","complete","authorName","Palleon Pharma","handle","avatarUrl","quoted","media",[],"aihot","/items/cgmgd0uacpvw0ldg90chnkblp","https://x.com/Palleon_Pharma/status/2046197937307345090","aacr26-floor","AACR 2026 现场信号","kind","x_search","firstParty","iconUrl","ok","changelogVersion","2026-10-23T01:25","enEditionEnabled"]